{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Negative+Breast+Carcinoma&page=26", "query": { "condition": "HER2 Negative Breast Carcinoma", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 684, "total_pages": 69, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Negative+Breast+Carcinoma&page=27&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Negative+Breast+Carcinoma&page=25&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T10:43:23.693Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01576666", "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dose Escalation", "Safety", "Preliminary Efficacy", "Advanced Solid Tumors", "Metastatic Breast Cancer", "Advanced Pancreatic Adenocarcinoma", "Metastatic Colorectal Cancer", "Recurrent Glioblastoma Multiforme", "Gastric Cancer", "Gastroesophageal Junction Cancer", "Triple Negative Metastatic Breast Cancer", "Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer" ], "interventions": [ { "name": "LDE225", "type": "DRUG" }, { "name": "BKM120", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2012-07", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-10-17T10:43:23.693Z", "location_count": 13, "location_summary": "Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01576666" }, { "nct_id": "NCT05867251", "title": "Study of AVZO-021 in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "HR+/HER2- Breast Cancer", "HR+, HER2-, Advanced Breast Cancer", "CCNE1 Amplification", "Epithelial Ovarian Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer", "Endometrial Cancer", "TNBC - Triple-Negative Breast Cancer" ], "interventions": [ { "name": "AVZO-021", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avenzo Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 430, "start_date": "2023-08-30", "completion_date": "2030-01-31", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-17T10:43:23.693Z", "location_count": 11, "location_summary": "New Haven, Connecticut • Sarasota, Florida • Tampa, Florida + 8 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Mineola", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05867251" }, { "nct_id": "NCT03018080", "title": "Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast - Female", "Male Breast Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2017-06-12", "completion_date": "2022-08-05", "has_results": true, "last_update_posted_date": "2023-08-04", "last_synced_at": "2026-10-17T10:43:23.693Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03018080" }, { "nct_id": "NCT01572727", "title": "A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "BKM120 matching placebo", "type": "DRUG" }, { "name": "BKM120", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 416, "start_date": "2012-08", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2017-03-09", "last_synced_at": "2026-10-17T10:43:23.693Z", "location_count": 21, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 17 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Greenbrae", "state": "California" }, { "city": "Greenwood Village", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01572727" }, { "nct_id": "NCT03359954", "title": "Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor Positive", "HER2/Neu Negative", "Invasive Breast Carcinoma", "Progesterone Receptor Positive" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2017-11-16", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-17T10:43:23.693Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03359954" }, { "nct_id": "NCT04134884", "title": "Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer", "Triple Negative Breast Cancer", "Hormone Receptor Positive Tumor" ], "interventions": [ { "name": "Talazoparib", "type": "DRUG" }, { "name": "ASTX727", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kathy Miller", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2020-04-01", "completion_date": "2024-03-14", "has_results": false, "last_update_posted_date": "2024-03-22", "last_synced_at": "2026-10-17T10:43:23.693Z", "location_count": 2, "location_summary": "Indianapolis, Indiana • Winston-Salem, North Carolina", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04134884" }, { "nct_id": "NCT02900664", "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma" ], "interventions": [ { "name": "PDR001", "type": "BIOLOGICAL" }, { "name": "ACZ885", "type": "BIOLOGICAL" }, { "name": "CJM112", "type": "BIOLOGICAL" }, { "name": "TMT212", "type": "DRUG" }, { "name": "EGF816", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 283, "start_date": "2016-08-23", "completion_date": "2021-03-17", "has_results": false, "last_update_posted_date": "2022-03-29", "last_synced_at": "2026-10-17T10:43:23.693Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02900664" }, { "nct_id": "NCT00903006", "title": "Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "MK-0646", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 11, "start_date": "2009-11", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2015-02-02", "last_synced_at": "2026-10-17T10:43:23.693Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00903006" }, { "nct_id": "NCT05252416", "title": "(VELA) Study of BLU-222 in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "HR+ Breast Cancer", "CCNE1 Amplification", "HER2-negative Breast Cancer", "Ovarian Cancer", "Endometrial Cancer", "Gastric Cancer", "Esophageal Adenocarcinoma", "Carcinosarcoma" ], "interventions": [ { "name": "BLU-222", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Blueprint Medicines Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2022-04-07", "completion_date": "2025-07-04", "has_results": false, "last_update_posted_date": "2025-11-28", "last_synced_at": "2026-10-17T10:43:23.693Z", "location_count": 19, "location_summary": "Little Rock, Arkansas • San Francisco, California • Stanford, California + 13 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05252416" }, { "nct_id": "NCT05966584", "title": "A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Benralizumab", "type": "DRUG" }, { "name": "fulvestrant or AIs) and PI3K inhibition (alpelisib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2023-07-06", "completion_date": "2024-08-02", "has_results": true, "last_update_posted_date": "2024-08-29", "last_synced_at": "2026-10-17T10:43:23.693Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05966584" } ] }